Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6976334 | 1.00 | LMNA (0.43) | LMNACYP2C9HTR6HPGDKMT2A | |
| SCHEMBL6970103 | 1.00 | LMNA (0.43) | LMNACYP2C9HTR6HPGDKMT2A | |
| Hydrochloric Acid SCHEMBL1936476 | 0.98 | HPGD (0.43) | LMNACYP2C9HTR6HPGDKMT2A | |
| Hydrochloric Acid SCHEMBL3279117 | 0.98 | HPGD (0.43) | LMNACYP2C9HTR6HPGDKMT2A | |
| SCHEMBL3995290 | 0.92 | HTR6 (0.47) | LMNACYP2C9HTR6HPGDKMT2A | |
| Hydrochloric Acid SCHEMBL8191203 | 0.91 | HTR6 (0.43) | LMNACYP2C9HTR6HPGDKMT2A | |
| SCHEMBL3996877 | 0.83 | HPGD (0.39) | HTR6HPGDKMT2ASMN1; SMN2CHRM3 | |
| Hydrochloric Acid SCHEMBL6971380 | 0.82 | HPGD (0.41) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL4489366 | 0.80 | HTR6 (0.42) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL25829140 | 0.78 | HTR6 (0.36) | HTR6HPGDKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2331518-A1 | NEW BRADYKININ B1 ANTAGONISTS | Evotec AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| US-20020161006-A1 | 1,4-dihydropyridine compounds as bradykinin antagonists | KAWAMURA MITSUHIRO (US) | 2002-10-31 | — | — | US | disclosed |
| EP-0882044-B1 | 1,4-DIHYDROPYRIDINE COMPOUNDS AS BRADYKININ ANTAGONISTS | PFIZER (US) | 2002-07-17 | — | — | EP | disclosed |
| US-20020042421-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | OKUMURA YOSHIYUKI (JP) | 2002-04-11 | — | — | US | disclosed |
| WO-2002012235-A1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-02-14 | — | — | WO | disclosed |
| EP-1106615-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 2001-06-13 | — | — | EP | disclosed |
| US-6156752-A | Optically active 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC (US) | 2000-12-05 | — | — | US | disclosed |
| US-6131226-A | 2-SUBSTITUTED,3,5-BIS(METHOXYCARBONYL),4-(2,6-DIHALOPHENYL), 6-(1-((SUBSTITUTED)RING)PIPERAZIN-1,4-YLENE-CARBONYLMETHYL)-1, 4-DIHYDROPYRIDINES; FOR TREATING INFLAMMATION, PAIN, VIRAL INFECTIONS, CARDIOVASCULAR DISEASE, ALLERGIES, ASTHMA | PFIZER INC. (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0899261-A1 | Optical active 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 1999-03-03 | — | — | EP | disclosed |
| EP-0882044-A1 | 1,4-DIHYDROPYRIDINE COMPOUNDS AS BRADYKININ ANTAGONISTS | PFIZER INC. (US) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997030048-A1 | 1,4-DIHYDROPYRIDINE COMPOUNDS AS BRADYKININ ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161006-A1 | 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, HRH4 | LMNA 3127/4885CYP2C9 2001/4885HTR6 455/4885 |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | LMNA 594/4885CYP2C9 1388/4885HTR6 1204/4885 |
| US-20020042421-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, HRH4 | LMNA 4089/4885CYP2C9 775/4885HTR6 368/4885 |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | LMNA 704/4885CYP2C9 1449/4885HTR6 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.